The global cotinine screening devices market recorded sales worth USD 429.9 Million in the year 2021. The market is expected to expand at a cumulative CAGR of 4.7% and will grow 1.4X by the end of 2032, in which the sales are anticipated to be worth USD 645 Million.
This growth can be attributed to the following factors:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | USD 450.3 Million |
| Market Value 2032 | USD 645 Million |
| CAGR 2022 to 2032 | 4.7% |
| Share of top 5 countries | 71.9% |
| Key Players | The Key players in the Cotinine Screening Devices market are Abbott Laboratories; AlcoPro; Jant Pharmacal Corporation; Sinocare Inc.; Mossman Associates; Nano-Ditech Corp; LifeSign LLC; ALFA Scientific; Ameritek USA.; Hangzhou Clongene Biotech Co.; and Germaine Laboratories; Inc. |
New Developments are enhancing Demand in the Global Market
High-performance Thin Layer Chromatography (HPTLC) has become a successful method for the creation and measurement of biomarkers. A significant development in the healthcare sector is the adoption of HPTLC as a reliable screening node for cotinine. The resurrected usage of HPTLC will open up new business prospects for manufacturers of cotinine screening equipment across the world.
The global market for cotinine screening devices is predicted to have greater competition over the coming ten years. The increased need for better methods of analyzing and diagnosing lung disorders has created new market possibilities for vendors. Another potential possibility for manufacturers is the use of cotinine in forensic testing and analysis.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Campaigns aimed at quitting smoking encourage people to try quitting smoking several times. These initiatives also seek to raise awareness of the many methods of quitting. Through these efforts, the negative effects of continued smoking are also emphasized.
People now have more information regarding nicotine and tobacco's ingredients. To monitor their health, people willingly undergo cotinine testing. Therefore, it is anticipated that cotinine screening tools will become more common in the next few years. To combat the growing prevalence of smoking habits, the medical community has partnered with top pharmaceutical firms. Long-term smoking's impacts on human lungs have emerged as a major field of study in medicine.
Cotinine is becoming crucial for Medical Treatments:
The fact that the alkaloid is widely used to treat PTSD is important from the standpoint of the growing market. Additionally, employing cotinine to treat mental illnesses has grown to be a well-known practice in the healthcare sector.
Cotinine aids in the management and control of schizophrenia and other conditions of a similar kind. Therefore, it is reasonable to anticipate that the world market for cotinine screening equipment will follow an upward development trajectory.
According to the American Lung Association, smoking is the primary factor in 1 out of every 5 fatalities in the country. Serious health problems are being caused by the growing number of adults and kids who smoke. In America, about 14% of individuals have a smoking addiction. The American Lung Association, therefore, imposes a national cigarette tax as well as other tobacco product taxes to control the use of tobacco and nicotine content.
In 2020, the typical state cigarette tax was about USD 1.82 per pack. Additionally, the American Lung Association developed health insurance plans, initiatives, and policies for smoke-free workplace regulations. These elements support the development of cotinine screening tools. Thus, in 2021, the United States of America had the greatest penetration rate for cotinine screening equipment.
In the year 2021, the cotinine screening devices market accounted for 8.1 percent of the global drug screening market, with sales of USD 5.3 billion. Increased use of cotinine screening devices in the workplace, the importance of drug-free recruiting, and the need for screening devices in insurance calculations are just a few of the important drivers driving this market's growth.
Cotinine is an alkaloid substance, formed in the human body after the consumption of nicotine. Cotinine is used for testing substance abuse in people because it stays in the human body for approximately 8 to 10 days. Cotinine is a biomarker indicating tobacco use.
Mandatory cotinine screening tests to hire employees is expected to rise the number of tests as well as products requirement in the market The sporting events have added nicotine to the list of drugs to be screened which is anticipated to propel the demand for cotinine screening devices around the world. Random checking of students at schools in North America as well as in East Asia also adds up to the growing demand for these devices. Moreover, compulsory screening of armed forces personnel before induction is another reason generating the demand for cotinine screening devices around the world over the forecast period.
The contract manufacturing of Cotinine screening devices in emerging countries is rising and favoring revenue generation for the key players. Marketing rights of manufacturers are undertaken by marketing entities to increase the promotion of cotinine screening devices, along with the license of available products to distribute exclusively in the other markets. The direct presence through the deployment of the salesforce in remote and smaller markets is one of the actions taken by players to increase the demand for these devices. E-Commerce and online trading through portals accessing online payment also attributes to the rising adoption of these devices for the detection of substance abuse.
Cassettes held a 62.9% market share, by the value of the overall cotinine screening devices market in the year 2021 and are expected to grow at a cumulative CAGR of 5.1% and will record sales worth USD 645 Million by the end of 2032. The growing tobacco use amongst the younger generation is one of the key factors which is fueling the demand for cotinine screening devices market around the globe.
Principal Consultant
| Particulars | Details |
|---|---|
| H1, 2021 | 4.69% |
| H1, 2022 Projected | 4.71% |
| H1, 2022 Outlook | 4.61% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 10 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 9 ↓ |
FMI delivers a comparative study of the global cotinine screening devices market's growth rates and development prospects. As a result of the impact of macro and industrial variables, the market is influenced by an increase in the patient base and product adoption rate.
Contract manufacturing of cotinine screening devices in emerging nations, and the introduction of e-commerce, and online trading with accessible online payment for such devices are all important trends in this market.
According to FMI, the market growth rate of cotinine screening devices is expected to decline by 09 Basis Point Share (BPS) in H1-2022 compared to H1-2021. Further comparison between the values for the H1-2022 outlook and H1-2022 projected showed a dip of 10 BPS.
Due to the lack of evaluation of inexpensive single-line test strips for cotinine screening, key aspects associated with the lowering of BPS are attributed to the differential qualitative dichotomization of smokers and non-smokers.
The importance of cotinine screening devices as significant indications of risk in life insurance testing, as well as the introduction of smoking cessation programs by regional governments, are two positives for the sector.
According to Future Market Insights, the cotinine screening devices market expanded at a cumulative CAGR of 4.2% between 2014 and 2021. The market grew 1.3X during this period and is expected to follow a similar trend over the forecast period.
According to the Centre for Disease Control and Prevention, approximately 34.1 million people in the USA smoked cigarettes in the year 2019. Along with the use of regular cigarettes, the use of vaping or electronic cigarettes has been on the rise in the past few years as well. According to a survey conducted in the USA, it was estimated that by the end of 2021, around 55 million people would be using e-cigarettes in the world.
As per CDC, around 33% of women smokers under Medicaid deny the use of tobacco during pregnancy. A recent study carried out indicated that a higher percentage of low-income pregnant women have a positive opinion about using urine cotinine tests to promote smoking cessation during pregnancy. The study also finds out that close to 90% of pregnant women favor nicotine testing during pregnancy but also fear if cotinine tests positive.
Various functional attributes of these screening devices give them a competitive edge over laboratory-based cotinine screening techniques, such as ease of use, convenience, and cost-effectiveness. These factors will help cotinine screening devices to gain preference in the world. These screening devices are also preferred by insurance providers, the majority used in smoking cessation programs and rehabilitation centers.
The cotinine screening devices are portable, which reduces the cost of logistics such as sample handling, sample delivery to the laboratories, generation of reports, etc. These devices also reduce the time taken in screening as they give the results within a few minutes. These devices can be used anywhere according to the preference of the consumers, which also improves the adoption rate. All these factors are constantly propelling the demand for this market around the globe.
Manufacturers are concentrating their efforts on developing cotinine screening equipment that is simple to use and provides quick findings. Manufacturers are responding to the sensitivities around distinct end-use cases by producing devices with features that comply with appropriate regulatory standards. The major players in the cotinine screening devices market are competing to increase the production of cassettes and strips, as these are the two most 'in-demand' forms.
The key players in this industry are entering into strategic agreements and partnerships acquiring subsidiaries to enhance their market presence and expand into the diagnostic testing market around the world.
In May 2018, AlcoPro Inc., a drug and alcohol testing products company announced the acquisition of Kahntact USA to improve its market presence around the world.
In June 2019, PTS Diagnostics announced their co-branded agreement with eTrueNorth, which is an integrated pharmacy-based clinical services network to enhance their services and close the gaps in healthcare and wellness screenings.
In January 2020, Jant Pharmacal Corporation announced the procurement of a contract with Vizient Inc., for their entire line of rapid test kits.
The cotinine screening devices market is consolidated with players such as Abbott Laboratories, AlcoPro, Jant Pharmacal Corporation, Sinocare Inc., Mossman Associates, Nano-Ditech Corp, LifeSign LLC, ALFA Scientific, Ameritek USA., Hangzhou Clongene Biotech Co., and Germaine Laboratories, Inc.
Future Market Insights expects the global cotinine screening devices market to expand at a cumulative CAGR of 4.7% over the forecast period (2022 to 2032) owing to the efforts taken by the key players to expand in the global market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The growing number of smokers worldwide is expected to provide high growth opportunities for test providers and cotinine screening device manufacturers. According to the National Institute of Drug Abuse, alcohol, tobacco, and illicit drugs together create an economic burden of nearly USD 700 billion in the USA through related costs, lost work productivity, and healthcare, which represents a vast opportunity for market growth.
Technological advances related to sample collection and efforts of manufacturers to create easy-to-use disposable test kits are expected to create high demand for cotinine screening products. Manufacturers are focusing on using samples other than urine, such as saliva and hair samples, which is less embarrassing for individuals being tested.
The decrease in the reimbursement rate for undergoing tobacco abuse testing may hamper the revenue growth of the stakeholders in the cotinine screening devices market. For instance in June 2015 Centers for Medicare and Medicaid Services reduced the reimbursement coverage to only two G codes for drug abuse testing, one for presumptive testing and one for definitive testing. The decrease in reimbursement may directly influence the number of drug abuse tests performed in the USA, as low reimbursement would lead to out-of-pocket spending for the customers. Although the cost of cotinine screening devices is low as compared to the other drug abuse testing devices cotinine testing volume can also be affected adversely with an overall decrease in the drug abuse reimbursement as many cotinine screening tests are performed as part of drug abuse testing.
The adoption of cotinine testing is limited to the general population for evaluation. Although various healthcare facilities carry out cotinine testing on regular basis for their employees many of them exclude current employees from it and carry out screening on new employees in the facility. Despite many employers across various countries adopting cotinine screening, the pace at which the adoption is rising is much slower compared to other screening tests used for drug abuse. The lack of immediate adverse effects makes cotinine testing’s importance go unnoticed by various employers. Low adoption of cotinine testing in rehabilitation centers as well is another reason, which may limit the growth of the market.
The American Lung Association has been playing a major role in the lives of people helping them to quit smoking. Their program Freedom From Smoking® has helped people for 35 years and is ranked one of the best tobacco cessation programs in the world. Other programs such as Smokefree, and Quit for Life also operate in the USA The more efforts taken by the government as well as non-profit organizations in the country to stop tobacco use are attributed to the high share of the USA in the cotinine screening devices market in North America. The USA accounted for 97.0% of the market share, by the value of the total market in North America in the year 2021.
Around 28% of the population, aged 15 and more in Germany smoked cigarettes regularly, in the year 2018. The government of Germany laid down some laws to curb smoking and protect the non-smoking people and the country such as The protection of Young Persons Act and the Federal Non-smokers protection act. These laws and other smoking cessation efforts which are taken by the government fuel the demand for cotinine screening devices in Germany. The sales of this market were recorded to be USD 40.0 Million in the year 2021, and the market is expected to grow at a cumulative CAGR of 4.9% over the forecast period in Germany.
According to the WHO tobacco statistics of India, the economic burden attributed to tobacco use in India during the year 2018 accounted for USD 27. 5 Billion. Nearly 29% of India’s population regularly smoked cigarettes or some other form of tobacco in the same year, which made India the second-largest consumer of tobacco in the world. Thus, India attributed the highest share of this market in South Asia, which was 29.5% in the year 2021.
The global cotinine screening devices market was valued at USD 429.9 Million in the year 2021 and is expected to expand at a CAGR of 4.7% over the forecast period (2022 to 2032)
Cassettes held a 62.9% market share, by the value of the overall cotinine screening devices market in the year 2021 and are expected to grow at a cumulative CAGR of 5.1% and will record sales worth USD 645 Million by the end of 2032. Since cassettes are the easiest device to test the presence of cotinine in the human body, they are the most preferred device in the industry. Various rapid testing kits used by workplace screening centers use cassettes as their diagnostic tools.
Saliva samples attributed 61.0% market share, by the value of the total market in the year 2021 and this segment is expected to expand at a CAGR of 4.8% over the forecast period with anticipated sales worth USD 382.8 Million by the end of 2029. Consumers prefer this type of sample for testing, which explains the high market share.
Laboratories held a 38.5% market share, by the value of the global market in the year 2021 with sales recorded worth USD 165.6 Million in the same year. The laboratories segment is anticipated to expand at a cumulative CAGR of 4.9% over the forecast period. Since there is an influx of funds for the research and development of innovative rapid testing kits, and the rising importance of smoking cessation around the world, laboratories are working round the clock for the same. Thus, they would be growing at a steady pace over the forecast period.
The key players in this market are focusing on exhibiting and showcasing their product lines at various conventions and conferences to gain publicity for their products and thereby expand their businesses.
Nano-Ditech Corporation announced the successful representation of the company’s product lines in the Medlab 2017 held in Dubai from March 6th to 9th.
LifeSign LLC announced its participation in the 71st AACC Annual Scientific Meeting & Clinical Lab Expo in August 2019.
In November 2017, Ameritek USA successfully exhibited their upcoming product line in the Medica 2016 held in Germany.
Hangzhou Clongene Biotech Co., in August 2019 announced that they exhibited their new product lines at the 2019 AACC Annual Scientific Meeting & Clinical Lab Expo.
Continuous efforts taken by various governments to stop the growing burden of smoking tobacco and drug abuse, decreasing the popularity of smoking amongst pregnant women, and growing interest in healthier lives will propel the demand for these screening devices in the upcoming years and present the manufacturers with many lucrative opportunities for growth and development.
| Attributes | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historic Data available for | 2014 to 2021 |
| Market Analysis | USD Million for value |
| Key Countries covered | USA, Canada, Germany, United Kingdom, France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, and South Africa. |
| Key Segments Covered | Device Type, Sample Type, End-User & Region |
| Key Companies Profiled | Abbott Laboratories; AlcoPro Inc.; Jant Pharmacal Corporation; Sinocare Inc.,(PTS Diagnostics); Mossman Associates; Nano-Ditech Corp; LifeSign LLC; ALFA Scientific; Ameritek USA.; Hangzhou Clongene Biotech Co.; Germaine Laboratories, Inc. |
| Report Coverage | Market Forecast, Competition Intelligence, Drivers, Restraints, Opportunities and Threats Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Customization and Pricing | Available upon request |
Cotinine screening devices are used to detect the presence of nicotine in a person’s body, which depicts the use of tobacco in the recent past.
The global cotinine screening devices market was valued at USD 429.9 Million in the year 2021 and is expected to expand at a CAGR of 4.7% over the forecast period (2022 to 2032)
The Key players in the Cotinine Screening Devices market are Abbott Laboratories, AlcoPro, Jant Pharmacal Corporation, Sinocare Inc., Mossman Associates, Nano-Ditech Corp, LifeSign LLC, ALFA Scientific, Ameritek USA., Hangzhou Clongene Biotech Co., and Germaine Laboratories, Inc.
Cassettes dominate the global cotinine screening devices market with a market share of more than 60% of the overall market in the year 2021.
1. Executive Summary 2. Market Overview 3. Key Market Trends 4. Key Success Factors 5. Global Market Demand (in Volume Units) Analysis 2014 to 2021 and Forecast, 2022 to 2029 6. Global Market - Pricing Analysis 7. Global Market Demand (in Value or Size in USD Million) Analysis 2014 to 2021 and Forecast, 2022 to 2029 8. Market Background 9. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Device Type 9.1. Cassettes 9.2. Strips 9.3. Reader 10. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Sample Type 10.1. Blood Sample 10.2. Urine Sample 10.3. Saliva Sample 11. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by End Users 11.1. Hospitals 11.2. Laboratories 11.3. Clinics 11.4. Workplace Screening Centers 12. Global Market Analysis 2014 to 2021 and Forecast 2022 to 2029, by Region 12.1. North America 12.2. Latin America 12.3. Europe 12.4. East Asia 12.5. South Asia 12.6. Oceania 12.7. Middle East and Africa (MEA) 13. North America Market Analysis 2014 to 2021 and Forecast 2022 to 2029 14. Latin America Market Analysis 2014 to 2021 and Forecast 2022 to 2029 15. Europe Market Analysis 2014 to 2021 and Forecast 2022 to 2029 16. South Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029 17. East Asia Market Analysis 2014 to 2021 and Forecast 2022 to 2029 18. Oceania Market Analysis 2014 to 2021 and Forecast 2022 to 2029 19. Middle East and Africa Market Analysis 2014 to 2021 and Forecast 2022 to 2029 20. Emerging Countries Market Analysis 2014 to 2021 and Forecast 2022 to 2029 21. Market Structure Analysis 22. Competition Analysis 22.1. Abbott 22.2. AlcoPro 22.3. Jant Pharmacal Corporation 22.4. Sinocare Inc. 22.5. Mossman Associates 22.6. Nano-Ditech Corp 22.7. LifeSign LLC 22.8. ALFA Scientific 22.9. Ameritek USA 22.10. Hangzhou Clongene Biotech Co. 22.11. Germaine Laboratories, Inc. 23. Assumptions and Acronyms Used 24. Research Methodology
Explore Healthcare Insights
View Reports
Cotinine Screening Devices Market
